MacroGenics director receives new equity awards

Q: What equity awards did MacroGenics (MGNX) grant to William K. Heiden?

William K. Heiden received stock options for 22,000 shares at an exercise price of $4.52 and a grant of 3,750 RSUs. These awards are part of his equity compensation as a director of MacroGenics.

Q: When do William K. Heiden’s new MacroGenics RSUs vest?

The newly granted 3,750 RSUs will vest one year after the May 19, 2026 grant date, or the day prior to the next annual meeting, if earlier. Upon vesting, each RSU converts into one share of MacroGenics common stock.

Q: What are the terms of William K. Heiden’s new MacroGenics stock options?

Heiden’s new stock options cover 22,000 shares of MacroGenics common stock with an exercise price of $4.52 per share. They vest in monthly 1/12th increments starting one month after grant and expire on May 19, 2036.

MACROGENICS INC director William K. Heiden reported routine equity compensation activity.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MACROGENICS INC director William K. Heiden reported routine equity compensation activity. On May 19, 2026, he was granted stock options for 22,000 shares of common stock with an exercise price of $4.52 per share, expiring on May 19, 2036. He also received a grant of 3,750 restricted stock units (RSUs) that will vest one year after the grant date or the day before the next annual meeting, if earlier. On May 18, 2026, 3,750 RSUs vested and were converted into 3,750 shares of common stock, bringing his direct common stock holdings to 114,750 shares. These transactions reflect awards and an RSU vesting/exercise, with no open‑market purchases or sales.

Insider Trade Summary

3,750 shares exercised/converted

Exercise 4 txns

Insider HEIDEN WILLIAM K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	3,750	$0.00	$0.00
Grant/Award	Stock Option (right to buy)	22,000	$0.00	$0.00
Exercise	Restricted Stock Unit	3,750	$0.00	$0.00
Exercise	Common Stock	3,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 3,750 contracts (Direct); Stock Option (right to buy) — 22,000 contracts (Direct); Common Stock — 114,750 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F2. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.
F3. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier
F4. The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Key Figures

Option grant size: 22,000 shares Option exercise price: $4.52 per share Option expiration: May 19, 2036 +4 more

7 metrics

Option grant size 22,000 shares Stock options for common stock granted May 19, 2026

Option exercise price $4.52 per share Exercise price of options expiring May 19, 2036

Option expiration May 19, 2036 Expiration date of 22,000-share option grant

New RSU grant 3,750 units RSUs granted May 19, 2026

RSUs vested and converted 3,750 shares RSUs vested May 18, 2026 and converted to common stock

Shares held after transactions 114,750 shares Total direct common stock holdings after May 18, 2026 conversion

Derivative exercises 3,750 shares Exercise or conversion of derivative security reported as code M

Key Terms

Restricted Stock Unit, Stock Option (right to buy, Exercise or conversion of derivative security, Annual Meeting of Stockholders, +1 more

5 terms

Restricted Stock Unit financial

"The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (right to buy financial

"security_title": "Stock Option (right to buy)"

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Annual Meeting of Stockholders financial

"one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026"

contingent right to receive financial

"Each restricted stock unit (RSU) represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did MacroGenics (MGNX) grant to William K. Heiden?

William K. Heiden received stock options for 22,000 shares at an exercise price of $4.52 and a grant of 3,750 RSUs. These awards are part of his equity compensation as a director of MacroGenics.

When do William K. Heiden’s new MacroGenics RSUs vest?

The newly granted 3,750 RSUs will vest one year after the May 19, 2026 grant date, or the day prior to the next annual meeting, if earlier. Upon vesting, each RSU converts into one share of MacroGenics common stock.

How many MacroGenics shares does William K. Heiden hold after these transactions?

After the reported transactions, William K. Heiden directly holds 114,750 shares of MacroGenics common stock. This total reflects the conversion of 3,750 RSUs into an equal number of common shares on May 18, 2026.

Did William K. Heiden buy or sell MacroGenics (MGNX) shares on the market?

The Form 4 shows no open‑market purchases or sales by William K. Heiden. Instead, it reports an RSU vesting and conversion into 3,750 shares and new equity grants of options and RSUs as compensation.

What are the terms of William K. Heiden’s new MacroGenics stock options?

Heiden’s new stock options cover 22,000 shares of MacroGenics common stock with an exercise price of $4.52 per share. They vest in monthly 1/12th increments starting one month after grant and expire on May 19, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/20/2026 - 04:14 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEIDEN WILLIAM K

(Last)

(First)

(Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/18/2026		M		3,750	A	⁽¹⁾	114,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	$0⁽¹⁾	05/18/2026		M			3,750	⁽²⁾	⁽²⁾	Common Stock	3,750	$0	0	D
Restricted Stock Unit	$0⁽¹⁾	05/19/2026		A		3,750		⁽³⁾	⁽³⁾	Common Stock	3,750	$0	3,750	D
Stock Option (right to buy)	$4.52	05/19/2026		A		22,000		⁽⁴⁾	05/19/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs vested on May 18, 2026, which was one day prior to the Issuer's 2026 Annual Meeting of Stockholders held on May 19, 2026.

3. The RSUs will vest one year after the date of grant, or the day prior to the next annual meeting, if earlier

4. The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards for whole shares) beginning one month from the date of grant.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR